BACKGROUND: Methylene blue dye (MBD) is being used as an alternative to isosulfan blue dye in sentinel lymph node (SLN) biopsies for breast cancer patients. Complications using MBD for SLN localization have not previously been reported. METHODS: A retrospective study was conducted of 24 consecutive patients who received MBD. Patients were given 3 to 5 cc of 1% MBD as peritumoral injections within the breast parenchyma and intradermally. Patients who developed local skin lesions at the injection site were queried regarding lesion appearance and when subsequent adjuvant therapy was initiated. RESULTS: Five of the 24 patients (21%) developed skin lesions at the injection site. Intradermal injections were discontinued, and only deep parenchymal injections were performed. All 5 patients had improvement of their skin lesions with silver sulfadiazine cream and no patient required debridement. Each patient received adjuvant therapy after surgery without delay. CONCLUSIONS: Our institution has experienced patients who developed skin lesions at the MBD injection site when using combined deep parenchymal and intradermal injections. With the increased use of MBD, caution should be used to avoid intradermal injections with SLN localization.
BACKGROUND:Methylene blue dye (MBD) is being used as an alternative to isosulfan blue dye in sentinel lymph node (SLN) biopsies for breast cancerpatients. Complications using MBD for SLN localization have not previously been reported. METHODS: A retrospective study was conducted of 24 consecutive patients who received MBD. Patients were given 3 to 5 cc of 1% MBD as peritumoral injections within the breast parenchyma and intradermally. Patients who developed local skin lesions at the injection site were queried regarding lesion appearance and when subsequent adjuvant therapy was initiated. RESULTS: Five of the 24 patients (21%) developed skin lesions at the injection site. Intradermal injections were discontinued, and only deep parenchymal injections were performed. All 5 patients had improvement of their skin lesions with silver sulfadiazine cream and no patient required debridement. Each patient received adjuvant therapy after surgery without delay. CONCLUSIONS: Our institution has experienced patients who developed skin lesions at the MBD injection site when using combined deep parenchymal and intradermal injections. With the increased use of MBD, caution should be used to avoid intradermal injections with SLN localization.
Authors: Jason David Cundiff; Yi-Zarn Wang; Gregory Espenan; Thomas Maloney; Arthur Camp; Laura Lazarus; Alan Stolier; Randy Brooks; Bruce Torrance; Shawn Stafford; James P O'Leary; Eugene A Woltering Journal: Ann Surg Date: 2007-02 Impact factor: 12.969
Authors: S P Somashekhar; S Zaveri Shabber; K Udupa Venkatesh; K Venkatachala; M M Vasan Thirumalai Journal: Indian J Surg Date: 2008-07-24 Impact factor: 0.656
Authors: Sreekar Devarakonda; Shawn Sam Thomas; Supriya Sen; Varghese Thomas; Reka Karuppusami; Anish Jacob Cherian; Pooja Ramakant; Deepak Thomas Abraham; Paul Mazhuvanchary Jacob Journal: Indian J Surg Oncol Date: 2021-01-16
Authors: Shirell E Klein; Joshua D Sosa; Alexander C Castonguay; Willmer I Flores; Lauren D Zarzar; Yangyang Liu Journal: Inorg Chem Front Date: 2020-09-25 Impact factor: 6.569